Attractor landscape analysis of colorectal tumorigenesis and its reversion

BackgroundColorectal cancer arises from the accumulation of genetic mutations that induce dysfunction of intracellular signaling. However, the underlying mechanism of colorectal tumorigenesis driven by genetic mutations remains yet to be elucidated.ResultsTo investigate colorectal tumorigenesis at a system-level, we have reconstructed a large-scale Boolean network model of the human signaling network by integrating previous experimental results on canonical signaling pathways related to proliferation, metastasis, and apoptosis. Throughout an extensive simulation analysis of the attractor landscape of the signaling network model, we found that the attractor landscape changes its shape by expanding the basin of attractors for abnormal proliferation and metastasis along with the accumulation of driver mutations. A further hypothetical study shows that restoration of a normal phenotype might be possible by reversely controlling the attractor landscape. Interestingly, the targets of approved anti-cancer drugs were highly enriched in the identified molecular targets for the reverse control.ConclusionsOur results show that the dynamical analysis of a signaling network based on attractor landscape is useful in acquiring a system-level understanding of tumorigenesis and developing a new therapeutic strategy.

[1]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[2]  Kwang-Hyun Cho,et al.  Attractor Landscape Analysis Reveals Feedback Loops in the p53 Network That Control the Cellular Response to DNA Damage , 2012, Science Signaling.

[3]  Gerhard Christofori,et al.  A causal role for E-cadherin in the transition from adenoma to carcinoma , 1998, Nature.

[4]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[5]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[6]  Tannaz Armaghany,et al.  Genetic alterations in colorectal cancer. , 2012, Gastrointestinal cancer research : GCR.

[7]  Bernd Groner,et al.  Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops , 2013, Current signal transduction therapy.

[8]  J. Gutkind,et al.  G-protein-coupled receptors and signaling networks: emerging paradigms. , 2001, Trends in pharmacological sciences.

[9]  B. Kholodenko,et al.  The dynamic control of signal transduction networks in cancer cells , 2015, Nature Reviews Cancer.

[10]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[11]  Hans Clevers,et al.  Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer , 2015, Cell.

[12]  Sharmistha Sarkar,et al.  A Two-Step Model for Colon Adenoma Initiation and Progression Caused by APC Loss , 2009, Cell.

[13]  H. Clevers,et al.  Linking Colorectal Cancer to Wnt Signaling , 2000, Cell.

[14]  Seung-Oe Lim,et al.  p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma , 2010, FEBS letters.

[15]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[16]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[17]  E. Gelfand,et al.  Arhgef1 is required by T cells for the development of airway hyperreactivity and inflammation. , 2007, American journal of respiratory and critical care medicine.

[18]  Jiri Bartek,et al.  Checking on DNA damage in S phase , 2004, Nature Reviews Molecular Cell Biology.

[19]  Gabriel S. Eichler,et al.  Cell fates as high-dimensional attractor states of a complex gene regulatory network. , 2005, Physical review letters.

[20]  A. Barabasi,et al.  Network-based in silico drug efficacy screening , 2016, Nature Communications.

[21]  D. Meek.  Tumour suppression by p53: a role for the DNA damage response? , 2009, Nature Reviews Cancer.

[22]  Andrew J Gentles,et al.  Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages , 2015, Proceedings of the National Academy of Sciences.

[23]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[24]  Randall T Moon,et al.  WNT and beta-catenin signalling: diseases and therapies. , 2004, Nature reviews. Genetics.

[25]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[26]  Simo V. Zhang,et al.  A map of human cancer signaling , 2007, Molecular systems biology.

[27]  Alan Wells,et al.  The dormancy dilemma: quiescence versus balanced proliferation. , 2013, Cancer research.

[28]  Kwang-Hyun Cho,et al.  Robustness and Evolvability of the Human Signaling Network , 2014, PLoS Comput. Biol..

[29]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[30]  Shiu-Ru Lin,et al.  APC, K-ras, and p53 Gene Mutations in Colorectal Cancer Patients: Correlation to Clinicopathologic Features and Postoperative Surveillance , 2005, The American surgeon.

[31]  H. Ichijo,et al.  Roles of MAPKKK ASK1 in stress-induced cell death. , 2003, Cell structure and function.

[32]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[33]  J. Cherfils,et al.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.

[34]  W. Birchmeier,et al.  Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. , 1994, Biochimica et biophysica acta.

[35]  Kwang-Hyun Cho,et al.  Network-based identification of feedback modules that control RhoA activity and cell migration. , 2015, Journal of molecular cell biology.

[36]  Kwang-Hyun Cho,et al.  Discovery of a kernel for controlling biomolecular regulatory networks , 2013, Scientific Reports.

[37]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[38]  H. Clevers,et al.  APC, Signal transduction and genetic instability in colorectal cancer , 2001, Nature Reviews Cancer.

[39]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[41]  Miguel Abal,et al.  APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. , 2006, Gastroenterology.

[42]  Kwang-Hyun Cho,et al.  A systems-biological study on the identification of safe and effective molecular targets for the reduction of ultraviolet B-induced skin pigmentation , 2015, Scientific Reports.

[43]  R. Fodde,et al.  Wnt/beta-catenin signaling in cancer stemness and malignant behavior. , 2007, Current opinion in cell biology.

[44]  J. Coxhead,et al.  Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[46]  Steven W. Cole,et al.  Molecular Pathways: Beta-Adrenergic Signaling in Cancer , 2011, Clinical Cancer Research.

[47]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[48]  T. Helikar,et al.  Emergent decision-making in biological signal transduction networks , 2008, Proceedings of the National Academy of Sciences.

[49]  Melanie I. Stefan,et al.  Molecules for memory: modelling CaMKII , 2007, BMC Systems Biology.

[50]  Sandra Zazo,et al.  PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential , 2014, Molecular Cancer Therapeutics.

[51]  Shengchao Ding,et al.  Recipes and mechanisms of cellular reprogramming: a case study on budding yeast Saccharomyces cerevisiae , 2011, BMC Systems Biology.

[52]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[53]  Oliver Sawodny,et al.  ON/OFF and Beyond - A Boolean Model of Apoptosis , 2009, PLoS Comput. Biol..

[54]  Takao Sakai,et al.  Integrins in invasive growth. , 2002, The Journal of clinical investigation.

[55]  M. L. Martins,et al.  Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes , 2013, PloS one.

[56]  P. Tsichlis,et al.  Regulation of the Akt kinase by interacting proteins , 2005, Oncogene.

[57]  S. Powers,et al.  Inducing stable reversion to achieve cancer control , 2016, Nature Reviews Cancer.

[58]  G Smith,et al.  The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma , 2005, Gut.

[59]  D. Schlaepfer,et al.  Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility. , 2009, Current opinion in cell biology.

[60]  Yutaka Kawakami,et al.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. , 2009, Cancer cell.

[61]  Kwang-Hyun Cho,et al.  The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor. , 2012, Journal of molecular cell biology.

[62]  Xiaoping Du,et al.  The interaction of Gα13 with integrin β1 mediates cell migration by dynamic regulation of RhoA , 2015, Molecular biology of the cell.

[63]  Riccardo Fodde,et al.  Wnt/β-catenin signaling in cancer stemness and malignant behavior , 2007 .

[64]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[65]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[66]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[67]  Bert Vogelstein,et al.  APC mutations occur early during colorectal tumorigenesis , 1992, Nature.

[68]  Henry Yang,et al.  Reversal of Aberrant Cancer Methylome and Transcriptome upon Direct Reprogramming of Lung Cancer Cells , 2012, Scientific Reports.

[69]  G M Bokoch,et al.  Activation of Rac and Cdc42 by integrins mediates cell spreading. , 1998, Molecular biology of the cell.

[70]  P. Morin,et al.  beta-catenin signaling and cancer. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[71]  C. Der,et al.  Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia , 1995, The Journal of cell biology.

[72]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[73]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[74]  Robert L. Sutherland,et al.  Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.

[75]  P. Waring,et al.  Cell death induced by the Fas/Fas ligand pathway and its role in pathology , 1999, Immunology and cell biology.

[76]  E. Barillot,et al.  A comprehensive modular map of molecular interactions in RB/E2F pathway , 2008, Molecular systems biology.

[77]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[78]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.